Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 10q

http://www.sec.gov/Archives/edgar/data/836564/000101968713003875/patriot_10q-083113.htm

$1.49M in license revenue.

7. Subsequent Events

We have evaluated subsequent events after the balance sheet date and based on our evaluation, management has determined that no subsequent events have occurred that would require recognition in the accompanying condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed in the accompanying notes.

During the period September 1, 2013 through October 9, 2013, we purchased 448,608 shares of our common stock at an aggregate cost of $40,009 pursuant to our stock buyback program.

Share
New Message
Please login to post a reply